背景:慢性使用甲基苯丙胺时肠道菌群密度和多样性的变化被认为是精神病和焦虑症状的原因,睡眠问题,和食欲不振。
目的:在这项安慰剂对照临床试验中,我们调查了益生菌嗜酸乳杆菌在改善长期使用甲基苯丙胺并伴有精神病症状的住院患者精神症状方面的作用.
方法:60例有3年以上甲基苯丙胺使用史的住院患者,根据简单的随机方法,我们被随机分配到两组中的一组,接受益生菌胶囊或安慰剂以及利培酮治疗8周。在第0周,第4周和第8周,使用简短精神病学评定量表(BPRS)对患者进行评估,贝克焦虑量表(BAI),匹兹堡睡眠质量指数(PSQI)简单的食欲营养问卷(SANQ),身体质量指数(BMI)。
结果:与对照组相比,接受益生菌的患者睡眠质量更好,更大的食欲,和较高的体重指数(在这些变量中,第8周的组和时间存在显着的交互作用(t=-3.32,B=-1.83,p=0.001,d=0.89),(t=10.50,B=2.65,p<.001,d=1.25)和(t=3.40,B=0.76,p<.001,d=0.30),分别。在改善精神病和焦虑症状方面,两组间差异无统计学意义。
结论:使用益生菌与改善睡眠质量有关,食欲增加,慢性使用甲基苯丙胺患者的体重指数增加。建议使用更大的样本量和更长期的病例随访进行更明确的临床试验。
BACKGROUND: Changes in the density and diversity of gut microbiota in chronic use of methamphetamine have been mentioned as contributors to psychotic and anxiety symptoms, sleep problems, and loss of appetite.
OBJECTIVE: In this placebo-controlled clinical
trial, we investigated the effect of the probiotic Lactobacillus Acidophilus in improving psychiatric symptoms among hospitalized patients with chronic methamphetamine use along with psychotic symptoms.
METHODS: 60 inpatients with a history of more than 3 years of methamphetamine use, were randomly assigned to one of two groups receiving either a probiotic capsule or placebo along with risperidone for 8 weeks based on a simple randomization method. In weeks 0, 4, and 8, patients were evaluated using the Brief Psychiatric Rating Scale (BPRS), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), Simple Appetite Nutritional Questionnaire (SANQ), and Body Mass Index (BMI).
RESULTS: Compared to the control group, patients receiving probiotics had better sleep quality, greater appetite, and higher body mass index (there were significant interaction effects of group and time at Week 8 in these variables (t = -3.32, B = -1.83, p = .001, d = 0.89), (t = 10.50, B = 2.65, p <.001, d = 1.25) and (t = 3.40, B = 0.76, p <.001, d = 0.30), respectively. In terms of the improvement of psychotic and anxiety symptoms, there was no statistically significant difference between the two groups.
CONCLUSIONS: The use of probiotics was associated with improved sleep quality, increased appetite, and increased body mass index in patients with chronic methamphetamine use. Conducting more definitive clinical trials with larger sample sizes and longer-term follow-up of cases is recommended.